Literature DB >> 15551730

Immunohistochemical analysis of biliary tract lesions.

Guangming Tan1, Asli Yilmaz, Barry R De Young, Cynthia Behling, Amy Lehman, Wendy L Frankel.   

Abstract

The distinction among inflammatory, benign, and malignant lesions of the biliary tract can at times be difficult. Several methods have been used, including immunohistochemistry (IHC), with variable success. We evaluated a panel of IHC stains to determine their utility in discriminating between bile duct lesions. Formalin-fixed, paraffin-embedded 4-microm sections from 12 inflammatory lesions, 10 bile duct adenomas, and 13 bile duct carcinomas were immunostained using a modified avidin-biotin-complex technique after epitope enhancement using antibodies for p53, Ki-67, and bcl-2. For p53 and bcl-2, greater than 1% of cells staining positive was interpreted as positive. The proliferation index was calculated by determining the number of Ki-67-positive cells in a 1000 cell count. In the inflammatory group, 0 of 12 reacted with anti-p53, 2 of 12 were positive with anti-bcl-2, and the proliferation index with was 22.9% +/- 3.9%. Two of 10 bile duct adenomas showed reactivity with anti-bcl-2, and none were decorated with anti-p53 or Ki-67. In the carcinoma group, 6 of 13 were positive with anti-p53, 9 of 12 were positive with anti-bcl-2, and the proliferation index was 35.3% +/- 5.5%. The proliferation rates differed significantly between groups (P < 0.05). The presence of bcl-2 and p53 immunoreactivity coupled with a high proliferative rate in a biliary tract lesion suggests a malignant process. A panel using these antibodies may be useful in difficult cases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15551730     DOI: 10.1097/00129039-200409000-00002

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  6 in total

1.  Proliferative index facilitates distinction between benign biliary lesions and intrahepatic cholangiocarcinoma.

Authors:  Christos G Tsokos; Gregor Krings; Funda Yilmaz; Linda D Ferrell; Ryan M Gill
Journal:  Hum Pathol       Date:  2016-07-07       Impact factor: 3.466

Review 2.  [The importance of immunohistochemistry for the diagnosis of cholangiocarcinomas].

Authors:  F Länger; R von Wasielewski; H H Kreipe
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

3.  Utility of DNA flow cytometry in distinguishing between malignant and benign intrahepatic biliary lesions.

Authors:  Kwun Wah Wen; Peter S Rabinovitch; Dongliang Wang; Aras N Mattis; Linda D Ferrell; Won-Tak Choi
Journal:  Virchows Arch       Date:  2020-04-15       Impact factor: 4.064

4.  Metallothionein expression is suppressed in primary human hepatocellular carcinomas and is mediated through inactivation of CCAAT/enhancer binding protein alpha by phosphatidylinositol 3-kinase signaling cascade.

Authors:  Jharna Datta; Sarmila Majumder; Huban Kutay; Tasneem Motiwala; Wendy Frankel; Robert Costa; Hyuk C Cha; Ormond A MacDougald; Samson T Jacob; Kalpana Ghoshal
Journal:  Cancer Res       Date:  2007-03-15       Impact factor: 12.701

5.  Intrahepatic cholangiocarcinoma mimicking hepatic inflammatory pseudotumor.

Authors:  Kumiko Kitajima; Hiroaki Shiba; Takuya Nojiri; Tadashi Uwagawa; Yuichi Ishida; Noriatsu Ichiba; Katsuhiko Yanaga
Journal:  J Gastrointest Surg       Date:  2007-03       Impact factor: 3.267

6.  High expression of L-type amino acid transporter 1 as a prognostic marker in bile duct adenocarcinomas.

Authors:  Nobuyuki Yanagisawa; Kiyomi Hana; Norihiro Nakada; Masaaki Ichinoe; Wasaburo Koizumi; Hitoshi Endou; Isao Okayasu; Yoshiki Murakumo
Journal:  Cancer Med       Date:  2014-06-02       Impact factor: 4.452

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.